Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on September 2, 2025. The company, incorporated in Delaware and headquartered in Miami, Florida, operates in the medical device sector. The filing specifically addresses a clinical milestone under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event and does not contain financial statements or quantitative financial data.
Material Changes and Clinical Milestone
The primary material event reported is the enrollment of the first patients in a multicenter, IRB-approved study. Key details include:
- Study Name: PRECISE Benign Thyroid Nodule (BTN) Study.
- Technology: Proprietary nsPFA™ Percutaneous Electrode System.
- Indication: Treatment of benign thyroid nodules (BTNs).
- Status: First patients successfully enrolled as of September 2, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the standard context of clinical trials. The outlook is implied through the progression of the PRECISE study, which represents a step toward potential commercialization for the treatment of BTNs. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study design and patient inclusion criteria.
- Confirm the timeline for subsequent study milestones (e.g., data readouts, interim results) not detailed in this 8-K.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this filing contains no financial data.
- Monitor regulatory communications regarding the nsPFA™ system's approval pathway for benign thyroid nodules.